Navidea Biopharmaceuticals (NYSE: NAVB) reported Q1 EPS of ($0.08), $0.02 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $752 thousand versus the consensus estimate of $900 thousand.

For earnings history and earnings-related data on Navidea Biopharmaceuticals (NAVB) click here.